65th ASH Annual Meeting & Exposition: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma

Symposia: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms Oral and Poster Abstracts
Oral

Research, Biological therapies, Antibody Therapy, adult, Translational Research, Lymphomas, non-Hodgkin lymphoma, Non-Biological therapies, Plasma Cell Disorders, drug development, pediatric, Diseases, Therapies, Lymphoid Malignancies, Radiation Therapy, Study Population, Human, Animal model

Grand Hall D (Manchester Grand Hyatt San Diego)

Moderators:

Kerry A Rogers, MD, The Ohio State University and Walter Hanel, MD, PhD,

Disclosures:

Rogers: Beigene: Consultancy; AstraZeneca: Consultancy; AbbVie: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Janssen: Consultancy; Loxo@Lilly: Consultancy; Novartis: Research Funding; Pharmacyclics: Consultancy.

9:30 AM

Qpctl Inhibition, By Targeting the Inflammatory Tumor Microenvironment, Constitutes a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma

Nicolas Di Siervi, PhD¹^*, Jasper Mullender, PhD²^*, María Victoria Revuelta, PhD³^*, Nahuel Zamponi, PhD³, Eloisi Caldas-Lopes, PhD⁴^*, Yusuke Isshiki, MD, PhD⁵, Wendy Beguelin, PhD⁵^*, Marcel Scheepstra, PhD²^*, Bastiaan Evers, PhD²^*, Jens Wuerthner, MD, PhD²^* and Leandro Cerchietti, MD⁶

¹Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY
²Scenic Biotech, Amsterdam, Netherlands
³Weill Cornell Medicine, New York, NY
⁴Weill Cornell Medicine, New York
⁵Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY
⁶Hematology and Oncology, Weill Cornell Medicine, New York, NY

9:45 AM

Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma

Maurizio Di Liberto, PhD¹^*, Yang Hu, PhD¹^*, Xiangao Huang, PhD¹^*, Giorgio Inghirami, MD¹^*, Kevin Wang, BS¹^*, Christina Lee, MD¹, Kami J. Maddocks, MD², Kristie A. Blum, MD³, Jia Ruan, MD, PhD⁴, John P. Leonard¹, Nancy L. Bartlett, MD⁵, Peter Martin, MD⁶, Olivier Elemento, PhD, MS, BS¹ and Selina Chen-Kiang, PhD¹

¹Weill Cornell Medicine, New York, NY
²The James Cancer Center, Ohio State University Hospital, Columbus, OH
³Winship Cancer Institute of Emory University, Atlanta, GA
⁴Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY
⁵Siteman, Washington University School of Medicine, St Louis, MO
⁶Weill Cornell Medicine, New York

10:00 AM

Genome-Wide CRISPR Screen Identifies MAD2L1BP, ANAPC15 and SLC39A7 As Intrinsic Regulators for Brentuximab Vedotin Sensitivity in Peripheral T-Cell Lymphoma Cells

Keito Suto¹^*, Masahiro Chiba¹^*, Takashi Ishio¹^*, Hideki Goto, MD, PhD¹^*, Tomoyuki Endo¹, Michiyuki Maeda²^*, Takanori Teshima, M.D., Ph.D.¹ and Masao Nakagawa, MD, PhD¹

¹Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
²Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan

10:15 AM

Discovery of Novel, First-in-Class Allosteric Modulators of MALT1 Scaffolding Function with Differentiated Pharmacology for NFκB-Driven Malignancies

Yi Yao^*, Yingzhi Bi^*, Huadong Sun^*, Kevin Ling^*, Huili Xia^*, Jun Kuai^*, Patrick DePaolo^*, Virginie Lafont^*, David Diller^*, Ara Aslanian^*, Samira Jaeger^*, Joe Wahle^*, Wei Liu^*, Ken Carson^*, Timothy Reilly^*, Gerry Harriman^* and Fang WANG, PhD^*

HotSpot Therapeutics, Boston

10:30 AM

BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model

Melissa L Comstock¹^*, Shyril O'Steen, PhD²^*, Yukang Lin, PhD¹^*, Donald Hamlin³^*, D Scott Wilbur, PhD³^*, Johnnie J. Orozco, MD, PhD⁴, Rainer F. Storb, MD¹, Roland B. Walter, MD, PhD, MS¹, Pinar Ataca Atilla, MD¹^*, Brian G Till¹, Geoffrey R Hill, MD¹, Brenda M. Sandmaier, MD¹ and Damian J Green, MD^1,3

¹Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
²Fred Hutchinson Cancer Center, Seattle, WA
³University of Washington, Seattle, WA
⁴Translational Science and Therapeutics Division, Fred Hutch Cancer Research Center, Seattle, WA

10:45 AM

Macropinocytosis As a Means of Selectively Targeting RAS-Mutant Multiple Myeloma

Nathan Beals, PhD¹^*, Craig Ramirez, PhD^1,2^*, Andy Hauser, PhD^1,2^*, Faith E. Davies, MD³, Dafna Bar-Sagi, PhD¹^* and Gareth J. Morgan, M.D., Ph.D.³^*

¹Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY
²TEZCAT Biosciences, New Haven, CT
³Perlmutter Cancer Center, Multiple Myeloma Research Program, NYU Grossman School of Medicine, NYU Langone Health, New York, NY

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

605.O1.6 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma